11 citations
,
October 2001 in “Dermatologic Clinics” In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.
11 citations
,
September 1999 in “Journal of the European Academy of Dermatology and Venereology” This review examines various immunomodulatory therapies for cutaneous lymphoma and notes that they are most effective in the disease's early stages.
39 citations
,
May 2004 in “Clinics in Dermatology” This article reviews treatment options for cutaneous T-cell lymphoma, including skin-directed therapies and aggressive treatments for advanced cases, but reports no new clinical results.
28 citations
,
September 2014 in “Journal of Veterinary Internal Medicine” This study found that the novel drug VDC-1101 showed a 45% objective response rate in treating canine cutaneous T-cell lymphoma, offering a potential treatment option for this challenging disease.
This review examines the potential of CAR-T cell therapy as a transformative treatment for refractory autoimmune diseases, highlighting its mechanisms, clinical challenges, and promising strategies for precision immunotherapy despite issues like complex manufacturing and antigen escape.